The global pain management drugs market was worth US$ 41.2 Billion in 2019. Pain is a distressing feeling which can be caused due to various health issues such as osteoarthritis, chronic arthritis, diabetic neuropathy, multiple sclerosis and cancer. Pain mechanism is an intricate process, and there are several pain management drugs that provide relief by acting through various physiological functions. These medications are specific drugs that perform pharmacological actions on pain receptors and work against the discomfort-causing symptoms.
High prevalence of chronic pain diseases and increasing geriatric population are among the key factors driving the global pain management drugs market. In 2018, around 991 Million people across the globe were more than 60 years old. By 2024, we expect these figures to reach 1.18 Billion. With the prevalence of chronic pain being significantly higher in older adults, this represents a key factor driving the demand of pain management drugs. Additionally, the increasing number of hospitalization cases, a huge demand-supply gap for effective neuropathic pain management drugs, and application of innovative and advance therapies, are also catalyzing the growth of the market. Furthermore, increasing occurrence of chronic diseases such as cancer, arthritis, heart attacks and diabetes along with neurological issues are also boosting the global demand for these drugs. Moreover, factors such as rising healthcare expenditure, improving R&D, rising consumer awareness, and significant government support for improving healthcare services are also driving the growth of the market.Looking forward, IMARC Group expects the market to exhibit moderate growth during 2020-2025.
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Inc., Pfizer, Inc., Eli Lilly & Company, Endo International plc, F. Hoffmann-La Roche AG, Bausch Health Companies, Inc., Merck & Co. Inc., Allergen Inc., Novartis International AG, Johnson & Johnson Private Limited, GlaxoSmithKline Plc and Purdue Pharma L.P, etc.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at